20
total announcements
524412.BO · 15 min delayed
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities for the quarter and half year ended 30th September, 2026.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has approved the allotment of 11,50,000 Equity Shares of Rs. 10 /- each pursuant to Conversion of Fully Convertible Equity Share Warrants upon receipt of Rs. 47.85/- per warrant to the persons belonging to both promoter and non-promoter Category.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has released the scrutinizer's report for its 36th Annual General Meeting, where three resolutions were passed with no votes against them, including the appointment of a director and approval of related party transactions.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to the acquisition of shares by Nimit Rajesh Ghatalia, a promoter of the company. The disclosure reveals that Nimit Rajesh Ghatalia has acquired 1,500,000 shares, increasing his holding to 4.88% of the total capital of the company.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has disclosed a shareholding change under SEBI SAST Reg 29(1) 2011, where Nimit Rajesh Ghatalia has acquired 1,50,000 equity shares through warrant conversion, increasing his holding to 5.18%.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has disclosed under SEBI SAST Regulation 29(2) that promoter group members have acquired additional shares, increasing their combined stake to 42.01%.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has made a disclosure under SEBI PIT Reg. 2015, stating that promoters have been allotted equity shares due to the conversion of warrants.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd held its 36th Annual General Meeting (AGM) on September 30, 2026, where the company's financial performance for FY 2025-2026 was discussed, and resolutions were passed, including the appointment of a director and approval of related party transactions.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has approved the allotment of 11,50,000 Equity Shares of Rs. 10/- each pursuant to Conversion of Fully Convertible Equity Share Warrants upon receipt of Rs. 47.85/- per warrant to the persons belonging to both promoter and non-promoter Category.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has approved the allotment of 11,50,000 Equity Shares of Rs. 10/- each pursuant to Conversion of Fully Convertible Equity Share Warrants upon receipt of Rs. 47.85/- per warrant.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced the closure of its trading window for insiders, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced the Notice and Integrated Annual Report for its 36th Annual General Meeting, scheduled to be held on September 30, 2026. The report includes audited financial statements for the year ended March 31, 2026, and resolutions for the appointment of a director and approval of related party transactions.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced the notice of its 36th Annual General Meeting (AGM) for the FY 2025-26, to be held on September 30, 2026, through video conferencing. The AGM will consider the audited financial statements for the year ended March 31, 2026, and the appointment of a director in place of Mrs. Bina Ghatalia, who retires by rotation.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced a book closure from September 24 to September 30, 2026, for its 36th Annual General Meeting.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has published an extract of unaudited standalone financial results for the quarter and three months ended June 30, 2026, which have been considered, approved, and taken on record by the Board of Directors. The financial results have been published in 'News Hub' (English Newspaper) edition dated 15/08/2026 & in 'News Hub' (Marathi newspaper) edition dated 15/08/2026. The company has also uploaded the newspaper advertisement on its website.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, along with a limited review report and MD/CFO certification. The company's trading window will be open after 48 hours.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with the board of directors approving the results and the audit committee recommending them. The company has also attached a statement of deviation or variation in the utilization of funds raised through convertible warrants.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has scheduled a board meeting on 14th August 2026 to consider and approve the unaudited financial results for the quarter ended 30th June 2026.
Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd has allotted 2,520,000 equity shares to promoters and non-promoters at Rs. 47.85 per warrant, following the conversion of 2,520,000 warrants. The company's issued and paid-up capital has increased to Rs. 33,354,303.